SCHEDULE 13D/A: Nautilus Biotechnology Insider Parag Mallick Boosts Stake to 17.4% Following New Option Grant

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.4% of outstanding common stock, primarily through direct holdings and a recent option grant.

Summary

• Parag Mallick, the Reporting Person, beneficially owns an aggregate of 22,263,911 shares of Nautilus Biotechnology, Inc. common stock.
• This represents 17.4% of the Issuer's outstanding shares, calculated based on 126,148,469 shares outstanding as of February 21, 2025, plus 1,584,019 shares issuable from options held by Mr. Mallick.
• Mr. Mallick has sole voting and dispositive power over 22,063,911 shares, which includes 20,479,892 directly owned shares and 1,584,019 shares issuable upon option exercise.
• He shares voting and dispositive power over an additional 200,000 shares held by The Dream Finder Foundation, where he serves as President.
• Of the options, 942,351 shares are vested and exercisable within 60 days of March 3, 2025.
• On March 3, 2025, Mr. Mallick was granted an option to purchase an additional 280,000 shares of the Issuer's Common Stock.
• Unvested options typically vest over time, subject to continued service, but 100% immediate vesting occurs if employment is terminated without cause or for good reason within a specific period around a change in control.

Sentiment

Score: 7

Explanation: The document indicates increased insider ownership and a new option grant, which are generally positive signals of confidence from a key individual. There are no negative financial or operational details disclosed.

Positives

• Increased insider ownership by Parag Mallick to 17.4% signals strong confidence in Nautilus Biotechnology's future prospects.
• The grant of 280,000 new stock options to a key insider aligns his financial interests directly with long-term shareholder value.
• Provisions for accelerated vesting of options upon certain change-of-control events provide an incentive for continued service and could facilitate future strategic transactions.

Risks

• The vesting of unvested options is contingent on the Reporting Person's continued service, meaning a departure could impact his beneficial ownership and the company's stability.
• The accelerated vesting clause tied to a change in control could potentially lead to a significant number of shares entering the market if such an event occurs and employment is terminated, potentially impacting share price.

Future Outlook

The document primarily details a change in beneficial ownership and an option grant, rather than providing a forward-looking business outlook. However, the terms of option vesting, particularly accelerated vesting upon a change in control, suggest potential future corporate actions or strategic considerations that could impact the company's structure or ownership.

Industry Context

This filing reflects an insider's increased stake in Nautilus Biotechnology, a company operating in the biotechnology sector. Such an increase in ownership by a key individual, especially through new option grants, is generally viewed positively as it aligns management's interests with long-term shareholder value, a common practice in growth-oriented biotech firms where intellectual property and key personnel are critical assets.

Comparison to Industry Standards

• This filing is a standard Schedule 13D amendment for reporting changes in beneficial ownership by a significant shareholder.
• The percentage of ownership (17.4%) for an individual insider is substantial and indicates a strong vested interest, which is not uncommon for founders or key executives in early to mid-stage biotechnology companies.
• For instance, in similar biotech firms like Illumina or Pacific Biosciences, key founders or executives often maintain significant stakes, though the exact percentages vary widely based on company stage, funding rounds, and public float.
• The option grant and vesting terms are typical for executive compensation packages in the biotech industry, designed to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• Parag Mallick and his spouse share voting and dispositive power over 200,000 shares of Common Stock owned by The Dream Finder Foundation, where Dr. Mallick is President. This constitutes a related party arrangement regarding shared control over shares.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling confidence and aligning interests. The potential for accelerated vesting upon a change in control could impact future share dilution or market liquidity.
• Employees: The vesting terms for options, particularly the accelerated vesting clause, could be a model for other key personnel, influencing retention and motivation.

Next Steps

• Continued service by Parag Mallick for unvested options to vest over time.
• Potential exercise of options by Parag Mallick, particularly the 942,351 shares exercisable within 60 days.
• Future SEC filings (e.g., Forms 4 or 5) by Parag Mallick to report changes in ownership or transactions.

Key Dates

Keywords

Nautilus Biotechnology, Parag Mallick, Schedule 13D, Beneficial Ownership, Common Stock, Stock Options, Insider Ownership, Biotechnology, SEC Filing, Corporate Governance